Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of AAV components by the innate immune system also leads to the AAV-directed adaptive immune response and potential loss of transgene expression in transduced cells (Mingozzi et al., 2007; Xiang et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Mingozzi et al., 2007
In the citing paper
“Early successes in this field were initially dampened by reports of patients who developed vector insertion-related leukemias directly linked to the viral platform used for transgene delivery11–18.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [12]
In the citing paper
“Evidence from early clinical trials, along with subsequent laboratory studies, suggest that CD8+ T cell responses against AAV capsid target transduced hepatocytes (16–18).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [17]
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [5]
In the citing paper
“Although AAV infection is non-pathogenic in humans, initial exposure induces humoral and cellular anti-capsid response that are reactive to rAAV due to capsid similarity (4, 5).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationMemory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,571
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Wang, L., Nichols, T. C., Read, M. S., Bellinger, D. A., & Verma, I. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0031 · Cited by 176
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 91
Self-citation
Research works printed but not linked: 1
- Muzyczka, N. & Berns, K.I. Parvoviridae: The Viruses and Their Replication, 2327–2359 (Lippincott Williams & Wilkins, Philadelphia, 2001).
Cited by
Items 201–300 of 765
Adeno-associated Virus: A Key to the Human Genome?
Henckaerts, E., & Linden, R. M. (2010) · Future Virology · doi:10.2217/fvl.10.48 · Cited by 71
“The investigators could demonstrate that the observed phenomenon was due to a cellular immune response directed at specific epitopes in the AAV capsid [32].”
BackgroundClinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia
Peyvandi, F., & Garagiola, I. (2019) · Haemophilia · doi:10.1111/hae.13816 · Cited by 72
Immunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 74
Gupta, S., Richards, S. M., Amaravadi, L. S., Piccoli, S. P., Desilva, B. S., Pillutla, R. C., Stevenson, L. F., Mehta, D. S., Carrasco‐Triguero, M., Neely, R. J., et al. (2017) · Bioanalysis · doi:10.4155/bio-2017-4974 · Cited by 75
Evolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 73
“co-infected with helper viruses will activate CD4+ and CD8+ T cells which then leaves a pool of memory T cells throughout the lifetime [65].”
BackgroundTessitore, A., Faella, A., O’Malley, T. M., Cotugno, G., Doria, M., Kunieda, T., Matarese, G., Haskins, M. E., & Auricchio, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300325 · Cited by 73
Lévy, C., Fusil, F., Amirache, F., Costa, C., Girard-Gagnepain, A., Négre, D., Bernadin, O., Garaulet, G., Rodríguez, A., Nair, N., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13520 · Cited by 72
Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-122 · Cited by 69
“Secondly, prior infection of the patients with natural or recombinant AAVs leads to formation of memory CD8+ T cells which readily undergo activation upon re-exposure to the AAV capsids [8,9].”
The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes
Wang, J., Faust, S. M., & Rabinowitz, J. E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.017 · Cited by 75
“transgene expression appeared to be mediated by the cytotoxic T lymphocyte destruction of transduced hepatocytes [79–81].”
BackgroundInfluentialRescuing the Failing Heart by Targeted Gene Transfer
Kawase, Y., Ladage, D., & Hajjar, R. J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.023 · Cited by 77
Srivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 71
“Furthermore, the triple-mutant AAV2 vectors were documented to be less immunogenic since they minimize the cytotoxic T cell response by avoiding phosphorylation, ubiquitination, and proteasome-mediated degradation.(91,96,98) The NextGen AAV2 vectors have also been used in a phase I/II clinical trial and have shown cli…”
BackgroundSabatino, D. E., Nichols, T. C., Merricks, E., Bellinger, D. A., Herzog, R. W., & Monahan, P. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-394596-9.00006-8 · Cited by 66
“Unfortunately, this conclusion also cannot be tested in the hemophilia B mouse.(248) Other groups responded to the clinical trial results by returning to the hemophilia B mice to examine and optimize AAV vector design and to address the hypothesis that more highly efficient FIX vectors might direct hepatic FIX express…”
BackgroundResultInfluentialSelf-citationGene Therapy with Helper-Dependent Adenoviral Vectors: Current Advances and Future Perspectives
Vetrini, F., & Ng, P. (2010) · Viruses · doi:10.3390/v2091886 · Cited by 77
The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67
“This was linked to increases in circulating AAV capsid-specific CD8 T cells that presumably attacked and destroyed the AAV-transduced cells.(8) Most humans are infected with AAVs”
BackgroundSelf-citationIn utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease
Bose, S. K., White, B. M., Kashyap, M. V., Dave, A., De Bie, F. R., Li, H., Singh, K., Menon, P., Wang, T., Teerdhala, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24443-8 · Cited by 67
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease
Spencer Chapman, M., Cull, A. H., Ciuculescu, M. F., Esrick, E. B., Mitchell, E., Jung, H., O’Neill, L., Roberts, K., Fabre, M. A., Williams, N., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02636-6 · Cited by 67
Cardiac gene therapy with SERCA2a: From bench to bedside
Gwathmey, J. K., Yerevanian, A. I., & Hajjar, R. J. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.11.011 · Cited by 75
“This response is dose dependent and in clinical trials to treat hemophilia or liportein lipase deficiency, higher doses (>1013 viral genomes) were associated with activation of capsid specific T cells and elimination of the transgene [104] [105].”
BackgroundExtracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity
You, Y., Tian, Y. P., Guo, R., Shi, J., Kwak, K. J., Tong, Y., Estania, A. P., Hsu, W., Liu, Y., Hu, S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae883 · Cited by 71
Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Haurigot, V., Mingozzi, F., Buchlis, G., Hui, D. J., Chen, Y., Basner-Tschakarjan, E., Arruda, V. R., Radu, A., Franck, H. G., Wright, J. F., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.73 · Cited by 66
Self-citationAronson, S. J., Veron, P., Collaud, F., Hubert, A., Delahais, V., Honnet, G., de Knegt, R. J., Junge, N., Baumann, U., Di Giorgio, A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.143 · Cited by 65
Self-citationKoilkonda, R., Yu, H., Talla, V., Porciatti, V., Feuer, W. J., Hauswirth, W. W., Chiodo, V., Erger, K. E., Boye, S. L., Lewin, A. S., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15388 · Cited by 65
López-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
“Together, these Together, these immune responses can limit the longevity of successful therapy [220]. immune responses can limit the longevity of successful therapy [220].”
BackgroundZiegler, R. J., Bercury, S. D., Fidler, J., Zhao, M. A., Foley, J., Taksir, T. V., Ryan, S., Hodges, B. L., Scheule, R. K., Shihabuddin, L. S., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.010 · Cited by 65
Goyenvalle, A., Wright, J., Babbs, A., Wilkins, V., García, L., & Davies, K. E. (2012) · Molecular Therapy · doi:10.1038/mt.2012.26 · Cited by 66
Efficient Gene Transfer to Kidney Mesenchymal Cells Using a Synthetic Adeno-Associated Viral Vector
Ikeda, Y., Sun, Z. Q., Xiao, R., Vandenberghe, L. H., & Humphreys, B. D. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040426 · Cited by 70
Raupp, C., Naumer, M., Müller, O. J., Gurda, B. L., Agbandje-McKenna, M., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00209-12 · Cited by 64
“Humoral immune responses are generated and memory CD8 T-cell responses have been observed in clinical trials (36, 40, 58).”
BackgroundAssessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors
Calcedo, R., Chichester, J. A., & Wilson, J. M. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.038 · Cited by 62
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
Lysosomal storage disease: Gene therapy on both sides of the blood–brain barrier
Aronovich, E. L., & Hackett, P. B. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.011 · Cited by 71
“Following intravenous delivery, systemic exposure to high doses of AAV vectors can trigger the activation of CD8 T-cell responses directed against the viral capsid in a dose-dependentmanner [99–102].”
BackgroundRetargeting transposon insertions by the adeno-associated virus Rep protein
Ammar, I., Gogol‐Döring, A., Miskey, C., Chen, W., Cathomen, T., Izsvák, Z., & Ivics, Z. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks317 · Cited by 69
“AAV-based vectors are involved in diverse gene therapy approaches such as clinical trials for the treatment of hemophilia B (24), rheumatoid arthritis (25) or Parkinson’s disease (26) with modest success and serious complications due to a cytotoxic T lymphocyte response to the AAV capsid (27).”
MethodLorain, S., Gross, D.-A., Goyenvalle, A., Danos, O., Davoust, J., & Garcia, L. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300377 · Cited by 62
Viral vectors as vaccine carriers
Ertl, H. C. J. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.06.001 · Cited by 65
Self-citationHemophilia gene therapy comes of age
George, L. A. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009878 · Cited by 62
“Although prior data support a decline in FIX:C and transaminase elevation as consistent with a capsid immune response, it is possible that new data from these trials support alternative models that have not yet been reported.(1,2,19,35) Before the initiation of the Spark clinical trial, Baxalta/Shire investigated an s…”
BackgroundResultGene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector
Barnard, A. R., Groppe, M., & MacLaren, R. E. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017293 · Cited by 60
“Consequently, antibodies against capsid antigens of wildtype AAVs can be detected in a significant percentage of humans (Mingozzi et al. 2007).”
BackgroundGene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
Rao, V. K., Kapp, D., & Schroth, M. K. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.12-a.s3 · Cited by 78
Brown, D., Altermatt, M., Dobreva, T., Chen, S., Wang, A., Thomson, M., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 60
“…ramifications of AAV capsid and transgene modifications with regard to innate (Duan, 2018; Hösel et al., 2012; Martino et al., 2011; Shao et al., 2018; Zaiss et al., 2008) and adaptive immune recognition (George et al., 2017; Manno et al., 2006; Mingozzi et al., 2007; Nathwani et al., 2011, 2014).”
BackgroundDesigning Heart Performance by Gene Transfer
Davis, J., Westfall, M. V., Townsend, D., Blankinship, M., Herron, T. J., Guerrero-Serna, G., Wang, W., Devaney, E., & Metzger, J. M. (2008) · Physiological Reviews · doi:10.1152/physrev.00039.2007 · Cited by 59
“Early work suggested that AAV vectors may be able to circumvent an immune reaction, but recent studies have now demonstrated that AAV vectors can elicit both a humoral and cellular immune response in a variety of animal models (116, 294, 432, 522, 579, 604).”
BackgroundImmunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
“This was associated with asymptomatic, self-limiting transaminitis, and corresponding changes in capsid-specific CTL population (5).”
BackgroundBarker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59
“It is estimated that up to 80% of the population have circulating antibodies against AAV2 [12], whereas 30–50% have antibodies with neutralizing activity [13,14].”
BackgroundMyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV
Sudres, M., Ciré, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgérault, F., Le Bec, C., Gross, D. A., Blouin, V., Ryffel, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.101 · Cited by 59
Miura, N., Shaheen, S. M., Akita, H., Nakamura, T., & Harashima, H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv008 · Cited by 60
Hemophilia gene therapy comes of age
George, L. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.587 · Cited by 58
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Blood · doi:10.1182/blood-2012-05-423210 · Cited by 55
Self-citationRecommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays
Gorovits, B., Fiscella, M., Havert, M., Koren, E., Long, B., Milton, M., & Purushothama, S. (2020) · The AAPS Journal · doi:10.1208/s12248-019-0403-1 · Cited by 57
“In addition to antibody-based immunity, a possibility of pre-existing and treatment-induced cellular immune response against GTx viral vector has been reported [21 – 23] and is commonly assessed by Enzyme-Linked ImmunoSpot analytical platform [23].”
Morizono, K., Ku, A. T., Xie, Y., Harui, A., Kung, S. K. P., Roth, M. D., Lee, B., & Chen, I. S. Y. (2010) · Journal of Virology · doi:10.1128/jvi.00435-10 · Cited by 61
Gene Replacement Therapy: A Primer for the Health-system Pharmacist
Petrich, J., Marchese, D., Jenkins, C., Storey, M., & Blind, J. E. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019854962 · Cited by 63
“However, there is currently no industry standard for the anti-vector immunoglobulin G (IgG) antibody titer permissible for each vector before dosing and no way to predict the potential expansion of capsid-specific memory CD8þ T cells.(19) Studies assessing the IgG humoral immune response have used different thresholds…”
BackgroundAdeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry
Large, E. E., Silveria, M., Zane, G. M., Weerakoon, O., & Chapman, M. S. (2021) · Viruses · doi:10.3390/v13071336 · Cited by 59
Ilyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K. (2021) · Science Advances · doi:10.1126/sciadv.abd0321 · Cited by 56
Gene therapy for cystic fibrosis: Challenges and prospects
Sui, H., Xu, X., Su, Y., Gong, Z., Yao, M., Liu, X., Zhang, T., Jiang, Z., Bai, T., Wang, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015926 · Cited by 60
“T cells on the duration of rAAV transduction administrated through airways, the involvement of CD T cells in the destruction of rAAV-transduced hepatocytes was reported in the rAAV2 hemophilia B clinical trial (Mingozzi et al., 2007).”
BackgroundHerzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
Wang, Z., Tapscott, S. J., Chamberlain, J. S., & Storb, R. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00201 · Cited by 53
“…neutralizing antibodies or memory T cells specific to viral capsid protein or transgene product were also suggested to prevent sustained transgene expression in recent human trials (Kessler et al., 1996; Xiao et al., 1996; Manno et al., 2006; Mingozzi et al., 2007; Mendell et al., 2010a).”
BackgroundAutophagy determines efficiency of liver‐directed gene therapy with adeno‐associated viral vectors
Hösel, M., Huber, A., Bohlen, S., Lucifora, J., Ronzitti, G., Puzzo, F., Boisgerault, F., Hacker, U. T., Kwanten, W. J., Klöting, N., et al. (2017) · Hepatology · doi:10.1002/hep.29176 · Cited by 53
“Additionally, as rapamycin also down-regulates effector T-cell responses to antigens including AAV capsids,((42)) while sparing/enhancing survival of regulatory T-cell responses,((43)) coadministration of rapamycin may represent not only a strategy FIG.”
BackgroundSelf-citationRevisiting the “New” Inflammatory Toxicities of Adeno-Associated Virus Vectors
Flotte, T. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.29117.trf · Cited by 56
Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates
Lai, C.-M., Estcourt, M. J., Himbeck, R. P., Lee, S.-Y., Yeo, I., Luu, C. D., Loh, B. K., Lee, M. W., Barathi, V. A., Villano, J., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.169 · Cited by 60
Immune barriers to successful gene therapy
Wu, T.-L., & Ertl, H. C. J. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.005 · Cited by 57
Self-citationBoisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Self-citationLin, J., Calcedo, R., Vandenberghe, L. H., Figueredo, J. M., & Wilson, J. M. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.033 · Cited by 53
“A clinical trial of AAV2 gene transfer in subjects with hemophilia B suggested a potential role of memory T cells to the AAV2 capsid in mediating toxicity, thereby expanding the spectrum of host–vector interactions that need to be considered (Mingozzi et al., 2007).”
Hudry, E., Aihara, F., Meseck, E. K., Mansfield, K. G., McElroy, C., Chand, D. H., Tukov, F. F., & Penraat, K. A. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.020 · Cited by 54
Recent advances in gene therapy for lysosomal storage disorders
Amalfitano, A., & Rastall, D. P. W. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s57682 · Cited by 62
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
“Antigen proteins are subsequently degraded and presented on the B-cell surface by MHC class II molecules, which facilitates interactions with helper CD4 + T-cells (Victora & Nussenzweig, 2012).”
InfluentialEllakwa, D. E., Mushtaq, N., Khan, S., Jabbar, A., Abdelmalek, M. A., Wadan, A. S., Ellakwa, T. E., & Raza, A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03076-w · Cited by 56
“For the transport of miRNA, common viral vectors like as lentiviral, adenoviral, retroviral, and adeno-associated viral (AAV) vectors have been used (Wang and Chen 2019; Mingozzi et al. 2007).”
Porcine Models of Muscular Dystrophy
Selsby, J. T., Ross, J. W., Nonneman, D., & Hollinger, K. (2015) · ILAR Journal · doi:10.1093/ilar/ilv015 · Cited by 61
“The viral vector itself can also provoke an immune response in patients (Mendell, Rodino-Klapac et al. 2010; Mingozzi et al. 2007), which could interfere with transgene expression.”
BackgroundRecent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia
Ajufo, E., & Cuchel, M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0579-0 · Cited by 51
Samelson-Jones, B. J., Finn, J. D., Favaro, P., Wright, J. F., & Arruda, V. R. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.001 · Cited by 50
“Although currentHBgene therapy trials have shifted to alternative serotypes, the cellular immune response against AAV2 capsids remains the most extensively investigated.(6,8,12) The AAV-capsid immune response is also serotype and route of administration independent.”
BackgroundGene therapy: principles, challenges and use in clinical practice
Ay, C., & Reinisch, A. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02368-8 · Cited by 61
Roctavian gene therapy for hemophilia A
Samelson‐Jones, B. J., Small, J. C., & George, L. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011847 · Cited by 58
Activation of the Cellular Unfolded Protein Response by Recombinant Adeno-Associated Virus Vectors
Balakrishnan, B., Sen, D., Hareendran, S., Roshini, V., David, S., Srivastava, A., & Jayandharan, G. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053845 · Cited by 50
“In AAV2 mediated gene therapy, the concept of capsid protein dependent immunotoxicity is well documented [5,34] and several groups have shown that cellular cytoplasmic surveillance mechanisms such as the NF-kB signalling [35], MYD88 pathway or toll-like receptor (TLR-9) [36,37] signalling influence this process.”
BackgroundEvaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy
Gorovits, B., Azadeh, M., Buchlis, G., Fiscella, M., Harrison, T., Havert, M., Janetzki, S., Jawa, V., Long, B. R., Mahnke, Y. D., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00814-5 · Cited by 52
Chuah, M., Evens, H., & VandenDriessche, T. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12215 · Cited by 58
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · PubMed · doi:10.1182/asheducation-2012.1.375 · Cited by 48
Self-citationNicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 53
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
Hui, D. J., Basner-Tschakarjan, E., Chen, Y., Davidson, R. J., Buchlis, G., Yazicioglu, M., Pien, G. C., Finn, J. D., Haurigot, V., Tai, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.166 · Cited by 47
Self-citationThe Future of In Utero Gene Therapy
Peranteau, W. H., & Flake, A. W. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00445-y · Cited by 47
Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia
Pierce, G. F., Fong, S., Long, B. R., & Kaczmarek, R. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.12.005 · Cited by 50
Self-citationGenetic Therapeutic Approaches for Duchenne Muscular Dystrophy
Foster, H., Popplewell, L. J., & Dickson, G. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.099 · Cited by 52
“…by the generation of both cytotoxic and humoral immune responses to the capsid of various rAAVs (Manno et al ., 2006; Mingozzi and High, 2007; Mingozzi et al ., 2007b; Mendell et al ., 2010a; Bowles et al ., 2012), the development of which appears to be dose dependent in humans (Mingozzi et…”
Piguet, F., de Saint Denis, T., Audouard, E., Beccaria, K., André, A., Wurtz, G., Schatz, R., Alves, S., Sevin, C., Zerah, M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.105 · Cited by 45
Velazquez, V. M., Bowen, D. G., & Walker, C. M. (2009) · Blood · doi:10.1182/blood-2008-01-131375 · Cited by 46
Hemophilia Gene Therapy: The End of the Beginning?
Wolf, D. D., Singh, K., Chuah, M., & VandenDriessche, T. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.112 · Cited by 50
“52 If most transduced hepatocytes were to be recognized by CD8 + T cells, and thus be eliminated, a drop in FVIII expression would be expected.”
Gene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 50
“However, humans are frequently exposed to wild-type AAV viruses and AAV vector infusion at a high dose likely reactivated preexisting memory CTLs [167].”
BackgroundGernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
“The fact that it was not predicted in animal models can be due to the pre-existing immunity to AAV capsid in humans.(30,52,53) Even if monkeys are natural hosts of AAV, their pre-existing capsid-specific T cells differ from those of humans, with an effector phenotype compared to a memory phenotype in humans, and also…”
BackgroundLi, H., Lin, S.-W., Giles-Davis, W., Li, Y., Zhou, D., Xiang, Z. Q., High, K. A., & Ertl, H. C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.79 · Cited by 46
Self-citationImmune Responses to AAV in Canine Muscle Monitored by Cellular Assays and Noninvasive Imaging
Wang, Z., Storb, R. F., Lee, D., Kushmerick, M. J., Chu, B., Berger, C., Arnett, A. L. H., Allen, J. M., Chamberlain, J. S., Riddell, S. R., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.294 · Cited by 46
Fetal stem cell and gene therapy
Witt, R. G., MacKenzie, T. C., & Peranteau, W. H. (2017) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2017.05.003 · Cited by 46
Pierce, G. F., & Iorio, A. (2018) · Haemophilia · doi:10.1111/hae.13489 · Cited by 47
Self-citationGene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
Domm, J. M., Wootton, S. K., Medin, J. A., & West, M. L. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.07.006 · Cited by 48
Muscle as a Target for Supplementary Factor IX Gene Transfer
Hoffman, B. E., Dobrzynski, E., Wang, L., Hirao, L., Mingozzi, F., Cao, O., & Herzog, R. W. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.042 · Cited by 44
Self-citationEvaluation of Adeno-Associated Viral Vectors for Liver-Directed Gene Transfer in Dogs
Bell, P., Gao, G., Haskins, M. E., Wang, L., Sleeper, M., Wang, H., Calcedo, R., Vandenberghe, L. H., Chen, S.-J., Weisse, C., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.194 · Cited by 45
“An additional complication in humans could be the development of T cells against the capsid as observed in a clinical trial with AAV2 expressing factor IX (Manno et al. , 2006; Mingozzi et al. , 2007).”
BackgroundRincón, M. Y., Sarcar, S., Danso‐Abeam, D., Keyaerts, M., Mátrai, J., Samara-Kuko, E., Acosta‐Sanchez, A., Athanasopoulos, T., Dickson, G., Lahoutte, T., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.178 · Cited by 50
Arjomandnejad, M., Sylvia, K., Blackwood, M., Nixon, T., Tang, Q., Muhuri, M., Gruntman, A. M., Gao, G., Flotte, T. R., & Keeler, A. M. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.010 · Cited by 44
Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy
Sen, D., Balakrishnan, B., Gabriel, N., Agrawal, P., Roshini, V., Samuel, R., Srivastava, A., & Jayandharan, G. R. (2013) · Scientific Reports · doi:10.1038/srep01832 · Cited by 44
Regulatory and Exhausted T Cell Responses to AAV Capsid
Gernoux, G., Wilson, J. M., & Mueller, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.022 · Cited by 44
Exploiting Single-Cell Tools in Gene and Cell Therapy
Bode, D., Cull, A. H., Rubio-Lara, J. A., & Kent, D. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702636 · Cited by 46
AAV for pain: steps towards clinical translation
Beutler, A. S., & Reinhardt, M. (2009) · Gene Therapy · doi:10.1038/gt.2009.23 · Cited by 47
Paving the way towards precise and safe CRISPR genome editing
Śledziński, P., Dabrowska, M., Nowaczyk, M., & Olejniczak, M. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107737 · Cited by 45
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
“81,107 In fact, most of what is known about the T cell responses to AAV come from lessons learned from gene therapy clinical trials.”
Self-citationTargeted Gene Therapy for the Treatment of Heart Failure
Rapti, K., Chaanine, A. H., & Hajjar, R. J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.02.005 · Cited by 48
Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates
Verdera, H. C., Collaud, F., Riling, C. R., Sellier, P., Nordin, J. M. L., Preston, G. M., Cagin, U., Fabregue, J., Barral, S., Moya‐Nilges, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26744-4 · Cited by 45
Self-citationCoagulation Factor IX for Hemophilia B Therapy
Orlova, N. A., Kovnir, S. V., Vorobiev, I. I., & Габибов, А. Г. (2012) · Acta Naturae · doi:10.32607/20758251-2012-4-2-62-73 · Cited by 47
Li, C., Hirsch, M., DiPrimio, N., Asokan, A., Goudy, K., Tisch, R., & Samulski, R. J. (2009) · Journal of Virology · doi:10.1128/jvi.00278-09 · Cited by 42
Metadata
- Authors
- Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C. J., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- The University of Sydney (AU)
- Hemophilia Center of Western Pennsylvania (US)
- The Wistar Institute (US)
- Corresponding author
- High, Katherine A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-03-18
- Volume
- 13
- Issue
- 4
- Pages
- 419-422
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2007261697
- Cited by
- 748
- References
- 8
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 43 · 2023: 41 · 2022: 34 · 2021: 58 · 2020: 43 · 2019: 40 · 2018: 28 · 2017: 38 · 2016: 24 · 2015: 40 · 2014: 41 · 2013: 37 · 2012: 40
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1f32hl069647-01)
- National Heart, Lung, and Blood Institute (F32 HL69647, P01HL078810, T32HL007439)
- National Institute of Allergy and Infectious Diseases (P30AI045008)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Center for Research Resources (M01RR000056, M01RR000240)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, AAV capsid, CD8+ T cells, AAV serotype 2, gene transfer, T cell memory, T cell proliferation
- MeSH terms
- Dependovirus, Animals, Capsid, Humans, Lymphocyte Activation, Parvoviridae Infections, Peptides, Gene Transfer Techniques, CD8-Positive T-Lymphocytes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.